HIMS

NEUTRAL

$29.39 Live

Hims & Hers Health, Inc. · NYSE

Target $25.57 (-13.0%)

$13.74 52W Range $70.43

HIMS Hims & Hers Health, Inc. - Fundamental Analysis

NEUTRAL

Console Chart News

HIMS Stock | Fundamental Analysis & Investment Insights

NYSE • Healthcare • Drug Manufacturers - Specialty & Generic

Current Price Live

$29.39

Analyst Target

$25.57

-13.0% Downside

52W High

$70.43

52W Low

$13.74

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 28, 2026

Market cap

$6.7B

P/E

57.63

ROE

25.2%

Profit margin

5.5%

Debt/Equity

2.07

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

HIMS demonstrates strong operational health with a Piotroski F-Score of 7/9, signaling robust financial trends and efficiency. However, the stock is severely overvalued from a deterministic standpoint, trading at $29.39 against a Graham Number of $5.23 and an Intrinsic Value of $3.57. While revenue growth is strong (28.4%) and gross margins are impressive (73.83%), the valuation premium is extreme. This, combined with bearish insider selling and a negative technical trend, offsets the company's fundamental operational strengths.

Key Strengths

Strong Piotroski F-Score (7/9) indicating high financial health

Excellent Gross Margins (73.83%) providing significant pricing power

Consistent Revenue Growth (28.4% YoY and Q/Q)

Strong Return on Equity (ROE) of 25.23%

Healthy liquidity with a Current Ratio of 1.90 and Quick Ratio of 1.51

Key Risks

Extreme valuation gap between current price and deterministic fair value

Bearish insider activity, specifically consistent selling by the CFO

Negative Year-over-Year earnings growth (-17.40%)

High Debt/Equity ratio (2.07) compared to conservative benchmarks

Bearish technical trend (0/100) and price trading above analyst target ($25.57)

AI Fair Value Estimate

Based on comprehensive analysis

$18.5

-37.1% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Moderate

Value

Future

Past

Health

Dividend

AI Verdict

Operationally strong but fundamentally overpriced

Key drivers: Piotroski F-Score, Revenue Growth, Valuation Gap, Insider Selling

Confidence

90%

Value

20/100

Ref P/E, PEG, Graham Number

Positives

Forward P/E (21.31) is significantly lower than trailing P/E

Watchpoints

Price is ~5.6x the Graham Number
Price/Book is very high at 12.35
PEG ratio of 2.63 suggests overvaluation relative to growth

Future

75/100

Ref Growth rates

Positives

Strong 28.4% revenue growth
Recent massive Q/Q EPS growth (+266.7%)

Watchpoints

Negative YoY earnings growth
High volatility in quarterly earnings surprises

Past

65/100

Ref Historical trends

Positives

Successful transition from negative to positive EPS over 22 quarters
Strong 3Y and 5Y price appreciation

Watchpoints

Recent 6-month price decline of 39.1%

Health

85/100

Ref Altman Z-Score, Piotroski F-Score

Positives

Piotroski F-Score of 7/9 is strong
Current and Quick ratios indicate no immediate liquidity risk

Watchpoints

Debt/Equity ratio is elevated at 2.07

Dividend

0/100

Ref Yield, Payout

Positives

No standout positives identified.

Watchpoints

No dividend payments
0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$29.39

Analyst Target

$25.57

Upside/Downside

-13.0%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for HIMS and closest competitors.

Updated 2026-04-27

Company	5Y	3Y	1Y	6M	1M	1W
HIMS Hims & Hers Health, Inc. Primary	+138.0%	+153.6%	+3.2%	-39.1%	+51.6%	-5.2%
ACLX Arcellx, Inc. Peer	+580.9%	+279.9%	+59.8%	+50.1%	+63.7%	+0.1%
RGEN Repligen Corporation Peer	-46.2%	-22.0%	-17.6%	-26.6%	+7.4%	-10.4%
HQY HealthEquity, Inc. Peer	+11.9%	+34.2%	-2.5%	-13.9%	-0.8%	-7.9%
GRFS Grifols, S.A. Peer	-51.1%	+11.6%	+28.0%	-11.9%	+2.2%	-0.4%

HIM

Hims & Hers Health, Inc.

Primary

+138.0%

+153.6%

+3.2%

-39.1%

+51.6%

-5.2%

ACL

Arcellx, Inc.

Peer

+580.9%

+279.9%

+59.8%

+50.1%

+63.7%

+0.1%

RGE

Repligen Corporation

Peer

-46.2%

-22.0%

-17.6%

-26.6%

+7.4%

-10.4%

HQY

HealthEquity, Inc.

Peer

+11.9%

+34.2%

-2.5%

-13.9%

-0.8%

-7.9%

GRF

Grifols, S.A.

Peer

-51.1%

+11.6%

+28.0%

-11.9%

+2.2%

-0.4%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

57.63

21.31

2.63

12.35

2.85

3.08

41.23

$6.7B

Profitability

Profit margins and return metrics

Profit Margin 5.47%

Operating Margin 2.72%

Gross Margin 73.83%

ROE 25.23%

ROA 5.29%

Growth

Revenue and earnings growth rates

Revenue Growth +28.4%

Earnings Growth -17.4%

Q/Q Revenue Growth +28.41%

Q/Q Earnings Growth -20.8%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

2.07

High debt

Current Ratio

1.9

Good

Quick Ratio

1.51

Excellent

Cash/Share

$2.53

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.6B

Gross Margin

71.9%

Op. Margin

1.5%

Net Margin

3.3%

Total Assets

$2.2B

Liabilities

$1.6B

Equity

$0.5B

Debt/Equity

2.98x

Operating CF

$0.1B

CapEx

$-0.1B

Free Cash Flow

$-0.0B

FCF Yield

-4%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-11

$N/A

2026-02-23

$0.22

+20.8% surprise

2025-11-03

$0.06

-41.0% surprise

2025-08-04

$0.17

+3.2% surprise

Healthcare Sector Comparison

Comparing HIMS against 560 companies in the Healthcare sector (34 bullish, 167 neutral, 359 bearish)

P/E Ratio

57.63

This Stock

75.44

Sector Avg

-23.6% (Discount)

Return on Equity (ROE)

25.23%

This Stock

-88.14%

Sector Avg

-128.6% (Below Avg)

Profit Margin

5.47%

This Stock

-16.28%

Sector Avg

-133.6% (Weaker)

Debt to Equity

2.07

This Stock

2.66

Sector Avg

-22.2% (Less Debt)

Revenue Growth

28.4%

This Stock

124.04%

Sector Avg

-77.1% (Slower)

Current Ratio

1.9

This Stock

4.47

Sector Avg

-57.6% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
HIMS Hims & Hers Health, Inc.	NEUTRAL	$6.7B	57.63	25.2%	5.5%	$29.39
ACLX Arcellx, Inc.	BEARISH	$6.69B	-	-53.4%	-%	$114.39	Compare
RGEN Repligen Corporation	BEARISH	$6.67B	137.55	2.4%	6.6%	$118.29	Compare
HQY HealthEquity, Inc.	NEUTRAL	$6.66B	31.69	10.2%	16.4%	$77.96	Compare
GRFS Grifols, S.A.	NEUTRAL	$6.74B	12.83	6.2%	5.3%	$8.21	Compare

HIMS Hims & Hers Health, Inc.

NEUTRAL

Mkt Cap

$6.7B

P/E

57.6

ROE

25.2%

Price

$29.39

Compare with HIMS

RGEN Repligen Corporation

Compare with HIMS

HQY HealthEquity, Inc.

Compare with HIMS

Compare with HIMS

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-04-20	BOUGHTON SOLEIL	Officer	Sale	9,463	$283,890
2026-04-20	OKUPE OLUYEMI	Chief Financial Officer	Sale	19,645	$588,615
2026-04-20	OKUPE OLUYEMI	Chief Financial Officer	Option Exercise	12,553	$108,531
2026-04-17	OKUPE OLUYEMI	Chief Financial Officer	Sale	54,927	$1,457,305
2026-04-17	OKUPE OLUYEMI	Chief Financial Officer	Option Exercise	6,184	$30,982
2026-04-09	DUDUM ANDREW	Chief Executive Officer	Gift	422,933	-
2026-04-06	OKUPE OLUYEMI	Chief Financial Officer	Sale	3,975	$79,409
2026-04-06	OKUPE OLUYEMI	Chief Financial Officer	Option Exercise	3,975	$19,915
2026-03-20	OKUPE OLUYEMI	Chief Financial Officer	Sale	9,217	$219,067
2026-03-20	OKUPE OLUYEMI	Chief Financial Officer	Option Exercise	4,489	$22,490
2026-03-17	CHI MICHAEL Y	Chief Operating Officer	Sale	97,289	$2,402,065
2026-03-17	BOUGHTON SOLEIL	Officer	Sale	4,812	$118,808
2026-03-17	BECKLUND IRENE	Officer	Sale	5,529	$136,511
2026-03-13	CHI MICHAEL Y	Chief Operating Officer	Stock Award	72,108	-
2026-03-13	BOUGHTON SOLEIL	Officer	Stock Award	41,421	-

BOUGHTON SOLEIL

Officer

Sell

2026-04-20

9,463 shares · $283,890

OKUPE OLUYEMI

Chief Financial Officer

Sell

2026-04-20

19,645 shares · $588,615

OKUPE OLUYEMI

Chief Financial Officer

Option Exercise

2026-04-20

12,553 shares · $108,531

OKUPE OLUYEMI

Chief Financial Officer

Sell

2026-04-17

54,927 shares · $1,457,305

OKUPE OLUYEMI

Chief Financial Officer

Option Exercise

2026-04-17

6,184 shares · $30,982

DUDUM ANDREW

Chief Executive Officer

Gift

2026-04-09

422,933 shares

OKUPE OLUYEMI

Chief Financial Officer

Sell

2026-04-06

3,975 shares · $79,409

OKUPE OLUYEMI

Chief Financial Officer

Option Exercise

2026-04-06

3,975 shares · $19,915

OKUPE OLUYEMI

Chief Financial Officer

Sell

2026-03-20

9,217 shares · $219,067

OKUPE OLUYEMI

Chief Financial Officer

Option Exercise

2026-03-20

4,489 shares · $22,490

CHI MICHAEL Y

Chief Operating Officer

Sell

2026-03-17

97,289 shares · $2,402,065

BOUGHTON SOLEIL

Officer

Sell

2026-03-17

4,812 shares · $118,808

BECKLUND IRENE

Officer

Sell

2026-03-17

5,529 shares · $136,511

CHI MICHAEL Y

Chief Operating Officer

Stock Award

2026-03-13

72,108 shares

BOUGHTON SOLEIL

Officer

Stock Award

2026-03-13

41,421 shares

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K

2026-03-11

Hims & Hers Health, Inc. filed an 8-K on March 11, 2026, likely to announce its fourth-quarter and full-year financial results.

10-K

2026-02-23

HIMS filed its 10-K on February 23, 2026, providing a comprehensive overview of its business operations and financial condition. The filing includes detailed management analysis of financial results and a disclosure of key operational and market risk factors.

8-K

2026-02-23

Hims & Hers Health, Inc. likely reported its fourth quarter and full-year financial results in this 8-K filing.

8-K

2026-02-19

Hims & Hers Health, Inc. likely filed this 8-K to announce its fourth-quarter and full-year financial results for the fiscal year ending December 31, 2025.

8-K

2025-11-17

10-Q

2025-11-03

HIMS filed its 10-Q on November 3, 2025, which includes a dedicated section on risk factors under Item 1A. Due to the limited content provided, specific financial highlights and detailed risk disclosures are not available for analysis.

8-K

2025-11-03

Hims & Hers Health, Inc. likely filed this 8-K to report its third-quarter financial results for 2025.

8-K

2025-10-02

Hims & Hers Health, Inc. likely reported its third-quarter financial results in this 8-K filing.

8-K

2025-09-22

8-K

2025-09-05

8-K

2025-08-04

10-Q

2025-08-04

8-K

2025-06-17

8-K

2025-05-13

8-K

2025-05-09

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

HOLD

14 analysts

JP Morgan

2026-04-24

init

Overweight

B of A Securities

2026-04-24

Maintains

Neutral Neutral

B of A Securities

2026-04-16

Maintains

Neutral Neutral

TD Cowen

2026-03-27

Maintains

Hold Hold

Leerink Partners

2026-03-16

Maintains

Market Perform Market Perform

Barclays

2026-03-11

Maintains

Overweight Overweight

Citigroup

2026-03-10

Sell Neutral

Deutsche Bank

2026-03-10

Maintains

Hold Hold

B of A Securities

2026-03-10

Underperform Neutral

Needham

2026-03-09

Hold Buy

Past News Coverage

Recent headlines mentioning HIMS from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

HIMS

HIMS Hims & Hers Health, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!